GABA(A) receptor-modulating neuroactive steroid composition in patients with panic disorder before and during paroxetine treatment.

PubWeight™: 1.56‹?› | Rank: Top 4%

🔗 View Article (PMID 11772707)

Published in Am J Psychiatry on January 01, 2002

Authors

Andreas Ströhle1, Elena Romeo, Flavia di Michele, Augusto Pasini, Alexander Yassouridis, Florian Holsboer, Rainer Rupprecht

Author Affiliations

1: Max Planck Institute of Psychiatry, Munich, Germany. stroehle@mpipsykl.mpg.de

Articles citing this

Acute shift in glutamate concentrations following experimentally induced panic with cholecystokinin tetrapeptide--a 3T-MRS study in healthy subjects. Neuropsychopharmacology (2013) 1.67

Steroid hormone fluctuations and GABA(A)R plasticity. Psychoneuroendocrinology (2009) 1.27

Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. J Psychiatry Neurosci (2005) 1.03

Pharmacokinetic and behavioral effects of allopregnanolone in healthy women. Psychopharmacology (Berl) (2005) 0.95

GABA metabolism and transport: effects on synaptic efficacy. Neural Plast (2012) 0.94

Progesterone withdrawal increases the alpha4 subunit of the GABA(A) receptor in male rats in association with anxiety and altered pharmacology - a comparison with female rats. Neuropharmacology (2002) 0.94

Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. World J Biol Psychiatry (2016) 0.92

Up-regulation of neurosteroid biosynthesis as a pharmacological strategy to improve behavioural deficits in a putative mouse model of post-traumatic stress disorder. J Neuroendocrinol (2012) 0.92

The relevance of neuroactive steroids in schizophrenia, depression, and anxiety disorders. Cell Mol Neurobiol (2007) 0.87

Role of microsomal retinol/sterol dehydrogenase-like short-chain dehydrogenases/reductases in the oxidation and epimerization of 3alpha-hydroxysteroids in human tissues. Endocrinology (2007) 0.87

In a mouse model relevant for post-traumatic stress disorder, selective brain steroidogenic stimulants (SBSS) improve behavioral deficits by normalizing allopregnanolone biosynthesis. Behav Pharmacol (2010) 0.86

S-norfluoxetine microinfused into the basolateral amygdala increases allopregnanolone levels and reduces aggression in socially isolated mice. Neuropharmacology (2010) 0.85

Neurosteroids reduce social isolation-induced behavioral deficits: a proposed link with neurosteroid-mediated upregulation of BDNF expression. Front Endocrinol (Lausanne) (2011) 0.83

Neuropsychopharmacological properties of neuroactive steroids in depression and anxiety disorders. Psychopharmacology (Berl) (2005) 0.82

GABAA receptor-acting neurosteroids: a role in the development and regulation of the stress response. Front Neuroendocrinol (2014) 0.82

Oxidative imbalance and anxiety disorders. Curr Neuropharmacol (2014) 0.82

Neuroactive steroids and anxiety disorders. J Psychiatry Neurosci (2002) 0.81

Progesterone turnover to its 5α-reduced metabolites in the ventral tegmental area of the midbrain is essential for initiating social and affective behavior and progesterone metabolism in female rats. J Endocrinol Invest (2010) 0.80

Ethanol alters local cellular levels of (3α,5α)-3-hydroxypregnan-20-one (3α,5α-THP) independent of the adrenals in subcortical brain regions. Neuropsychopharmacology (2014) 0.79

Neurosteroids as neuromodulators in the treatment of anxiety disorders. Front Endocrinol (Lausanne) (2011) 0.76

Pregnenolone sulfate as a modulator of synaptic plasticity. Psychopharmacology (Berl) (2014) 0.76

Neuroactive steroid levels in patients with panic disorder. Am J Psychiatry (2003) 0.75

Lower allopregnanolone during pregnancy predicts postpartum depression: An exploratory study. Psychoneuroendocrinology (2017) 0.75

Studies of pharmacokinetic and pharmacodynamic properties of isoallopregnanolone in healthy women. Psychopharmacology (Berl) (2008) 0.75

Articles by these authors

Stress and the brain: from adaptation to disease. Nat Rev Neurosci (2005) 9.48

Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02

A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry (2012) 6.34

Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nat Neurosci (2012) 4.71

Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet (2007) 4.54

Dynamic DNA methylation programs persistent adverse effects of early-life stress. Nat Neurosci (2009) 4.53

Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet (2004) 3.91

Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73

The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest (2003) 3.62

FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. J Biol Chem (2004) 2.91

Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat Neurosci (2003) 2.79

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry (2008) 2.64

Meta-analysis of genome-wide association data identifies a risk locus for major mood disorders on 3p21.1. Nat Genet (2010) 2.46

RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. Cell (2007) 2.34

Auditory cortex is implicated in tinnitus distress: a voxel-based morphometry study. Brain Struct Funct (2013) 2.26

Genome-wide association study of major recurrent depression in the U.K. population. Am J Psychiatry (2010) 2.17

Using polymorphisms in FKBP5 to define biologically distinct subtypes of posttraumatic stress disorder: evidence from endocrine and gene expression studies. Arch Gen Psychiatry (2011) 2.09

Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. Arch Gen Psychiatry (2007) 2.05

The neuronal transporter gene SLC6A15 confers risk to major depression. Neuron (2011) 2.02

Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol (2002) 1.97

Enhanced and delayed stress-induced alcohol drinking in mice lacking functional CRH1 receptors. Science (2002) 1.93

Heterogeneity of DSM-IV major depressive disorder as a consequence of subthreshold bipolarity. Arch Gen Psychiatry (2009) 1.88

Polymorphisms in the FKBP5 gene region modulate recovery from psychosocial stress in healthy controls. Eur J Neurosci (2008) 1.88

Gene expression patterns associated with posttraumatic stress disorder following exposure to the World Trade Center attacks. Biol Psychiatry (2009) 1.85

Development of the brain's default mode network from wakefulness to slow wave sleep. Cereb Cortex (2011) 1.79

PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet (2008) 1.78

Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice. J Neurosci (2007) 1.70

Glutamatergic and dopaminergic neurons mediate anxiogenic and anxiolytic effects of CRHR1. Science (2011) 1.64

Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry (2004) 1.63

Polymorphisms of the glucocorticoid receptor gene and major depression. Biol Psychiatry (2006) 1.62

Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One (2010) 1.62

EPIBLASTER-fast exhaustive two-locus epistasis detection strategy using graphical processing units. Eur J Hum Genet (2010) 1.62

Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science (2009) 1.61

Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol Psychiatry (2005) 1.61

The Munich vulnerability study on affective disorders: premorbid polysomnographic profile of affected high-risk probands. Biol Psychiatry (2005) 1.57

Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron (2008) 1.57

Increased stress reactivity is associated with reduced hippocampal activity and neuronal integrity along with changes in energy metabolism. Eur J Neurosci (2012) 1.54

The combined dexamethasone/CRH test as a potential surrogate marker in depression. Prog Neuropsychopharmacol Biol Psychiatry (2005) 1.52

Putative biological mechanisms for the association between early life adversity and the subsequent development of PTSD. Psychopharmacology (Berl) (2010) 1.49

Activation and induction of NUR77/NURR1 in corticotrophs by CRH/cAMP: involvement of calcium, protein kinase A, and MAPK pathways. Mol Endocrinol (2002) 1.47

Clinical characteristics and treatment outcome in a representative sample of depressed inpatients - findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res (2008) 1.45

Plasma dehydroepiandrosterone levels are strongly increased in schizophrenia. J Psychiatr Res (2005) 1.44

Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression - a potential biomarker? Biol Psychiatry (2006) 1.44

P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder. Hum Mol Genet (2006) 1.42

Identification of glyoxalase-I as a protein marker in a mouse model of extremes in trait anxiety. J Neurosci (2005) 1.40

Clinical risk factors for weight gain during psychopharmacologic treatment of depression: results from 2 large German observational studies. J Clin Psychiatry (2015) 1.39

FK506 binding protein 5 shapes stress responsiveness: modulation of neuroendocrine reactivity and coping behavior. Biol Psychiatry (2011) 1.37

Interaction of FKBP5 gene variants and adverse life events in predicting depression onset: results from a 10-year prospective community study. Am J Psychiatry (2011) 1.33

Dreamed movement elicits activation in the sensorimotor cortex. Curr Biol (2011) 1.27

Altered processing of acoustic stimuli during sleep: reduced auditory activation and visual deactivation detected by a combined fMRI/EEG study. Neuroimage (2002) 1.26

Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? Nat Rev Drug Discov (2012) 1.22

Increased sleep pressure reduces resting state functional connectivity. MAGMA (2010) 1.21

Analysis of single nucleotide polymorphisms in genes in the chromosome 12Q24.31 region points to P2RX7 as a susceptibility gene to bipolar affective disorder. Am J Med Genet B Neuropsychiatr Genet (2006) 1.20

Long-term behavioral and neuroendocrine alterations following chronic social stress in mice: implications for stress-related disorders. Horm Behav (2007) 1.20

Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. Proc Natl Acad Sci U S A (2003) 1.20

Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry (2003) 1.19

Heritability of sleep electroencephalogram. Biol Psychiatry (2008) 1.19

Essential role of the unusual DNA-binding motif of BAG-1 for inhibition of the glucocorticoid receptor. J Biol Chem (2002) 1.19

Methodological aspects of clinical trials in tinnitus: a proposal for an international standard. J Psychosom Res (2012) 1.19

Neural correlates of dream lucidity obtained from contrasting lucid versus non-lucid REM sleep: a combined EEG/fMRI case study. Sleep (2012) 1.19

Overweight and obesity affect treatment response in major depression. Biol Psychiatry (2007) 1.18

Alterations in central neuropeptide expression, release, and receptor binding in rats bred for high anxiety: critical role of vasopressin. Neuropsychopharmacology (2004) 1.17

Depletion of the neural precursor cell pool by glucocorticoids. Ann Neurol (2010) 1.17

Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurol (2006) 1.17

Dexamethasone stimulated gene expression in peripheral blood is a sensitive marker for glucocorticoid receptor resistance in depressed patients. Neuropsychopharmacology (2012) 1.16

Effects of transgenic overproduction of CRH on anxiety-like behaviour. Eur J Neurosci (2002) 1.15

The involvement of FK506-binding protein 51 (FKBP5) in the behavioral and neuroendocrine effects of chronic social defeat stress. Neuropharmacology (2011) 1.15

Mutations of the Nogo-66 receptor (RTN4R) gene in schizophrenia. Hum Mutat (2004) 1.14

Brain-derived neurotrophic factor Val66Met polymorphism and dexamethasone/CRH test results in depressed patients. Psychoneuroendocrinology (2006) 1.14

Proteomics and metabolomics analysis of a trait anxiety mouse model reveals divergent mitochondrial pathways. Biol Psychiatry (2011) 1.14

Mining the human cerebrospinal fluid proteome by immunodepletion and shotgun mass spectrometry. Electrophoresis (2004) 1.13

Valproate and amitriptyline exert common and divergent influences on global and gene promoter-specific chromatin modifications in rat primary astrocytes. Neuropsychopharmacology (2009) 1.12

Functional MRI during sleep: BOLD signal decreases and their electrophysiological correlates. Eur J Neurosci (2004) 1.12

Effects of rapid eye movement sleep deprivation on fear extinction recall and prediction error signaling. Hum Brain Mapp (2011) 1.12

Evidence for VAV2 and ZNF433 as susceptibility genes for multiple sclerosis. J Neuroimmunol (2010) 1.12

Impaired repression at a vasopressin promoter polymorphism underlies overexpression of vasopressin in a rat model of trait anxiety. J Neurosci (2004) 1.11

Genetic markers for PTSD risk and resilience among survivors of the World Trade Center attacks. Dis Markers (2011) 1.11

Sleep spindles and hippocampal functional connectivity in human NREM sleep. J Neurosci (2011) 1.10

Transcriptional activities of the zinc finger protein Zac are differentially controlled by DNA binding. Mol Cell Biol (2003) 1.10

Functional microstates within human REM sleep: first evidence from fMRI of a thalamocortical network specific for phasic REM periods. Eur J Neurosci (2007) 1.10

The activated glucocorticoid receptor inhibits the transcription factor T-bet by direct protein-protein interaction. FASEB J (2007) 1.09

Mice selected for high versus low stress reactivity: a new animal model for affective disorders. Psychoneuroendocrinology (2008) 1.09

Forebrain CRHR1 deficiency attenuates chronic stress-induced cognitive deficits and dendritic remodeling. Neurobiol Dis (2011) 1.08

Substance P serum levels are increased in major depression: preliminary results. Biol Psychiatry (2003) 1.08

Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice. Psychoneuroendocrinology (2007) 1.08

Reduced hippocampal volumes associated with the long variant of the serotonin transporter polymorphism in major depression. Arch Gen Psychiatry (2004) 1.08

Ghrelin suppresses secretion of luteinizing hormone in humans. J Clin Endocrinol Metab (2007) 1.07

Individual stress vulnerability is predicted by short-term memory and AMPA receptor subunit ratio in the hippocampus. J Neurosci (2010) 1.07

Impact of high and low anxiety on cognitive performance in a modified hole board test in C57BL/6 and DBA/2 mice. Eur J Neurosci (2003) 1.07

High-affinity CRF1 receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response. Neuropsychopharmacology (2007) 1.06

Are obese adolescents and young adults at higher risk for mental disorders? A community survey. Obes Res (2002) 1.05

Activity of the GR in G2 and mitosis. Mol Endocrinol (2002) 1.05

Identification of a naturally occurring polymorphism in the promoter region of the norepinephrine transporter and analysis in major depression. Neuropsychopharmacology (2002) 1.05

Forced swim stress activates rat hippocampal serotonergic neurotransmission involving a corticotropin-releasing hormone receptor-dependent mechanism. Eur J Neurosci (2002) 1.05

Profiling of behavioral changes and hippocampal gene expression in mice chronically treated with the SSRI paroxetine. Psychopharmacology (Berl) (2008) 1.04

Effects of light or dark phase testing on behavioural and cognitive performance in DBA mice. Lab Anim (2006) 1.04